| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/10/2004 | US20040110151 Modulation of sentrin-2 expression |
| 06/10/2004 | US20040110150 Antisense oligonucleotides for controlling expression of tyrosine kinase interacting protein (EPHRIN-B2) and for treatment of hyperproliferative disorders |
| 06/10/2004 | US20040110149 Modulation of BUB1-beta expression |
| 06/10/2004 | US20040110148 Antisense oligonucleotides for controlling expression of polyamine biosynthetic enzymes and for treating hyperproliferative disorders |
| 06/10/2004 | US20040110147 Modulation of BAF53 expression |
| 06/10/2004 | US20040110146 Antisense oligonucleotides for controlling expression of cell surface adhesion molecule and for treatment of autoimmune disorders |
| 06/10/2004 | US20040110145 Modulation of MALT1 expression |
| 06/10/2004 | US20040110144 Modulation of EMAP-II expression |
| 06/10/2004 | US20040110143 Antisense oligonucleotides for controlling expression of liver receptor homologue -1 (LRH-1) for treatment of hyperproliferative disorders |
| 06/10/2004 | US20040110142 Modulation of AAC-11 expression |
| 06/10/2004 | US20040110140 Modulation of CDK9 expression |
| 06/10/2004 | US20040110139 Modulation of G protein-coupled receptor 3 expression |
| 06/10/2004 | US20040110131 Thrombospondin-1 type 1 repeat polypeptides |
| 06/10/2004 | US20040110127 Screening methods for identifying compounds which decrease HIV entry into a cell |
| 06/10/2004 | US20040109901 Compositions and methods for nutrition supplementation |
| 06/10/2004 | US20040109880 Cosmetic and/or pharmaceutical preparations |
| 06/10/2004 | US20040109878 Removal cancer, organ transplant and autoimmune cells from bone marrow, blood |
| 06/10/2004 | US20040109870 Therapeutic agent for acute hepatitis and chronic hepatitis including hepatic fibrosis and cirrhosis |
| 06/10/2004 | US20040109866 Immonotherapy complex containing antigen, antibodies, epitopes; binding to receptors |
| 06/10/2004 | US20040109861 Isolated protein complexes; screening analyzing; human t-cell leukemia virus |
| 06/10/2004 | US20040109860 Using immunoglobulins that blocks nerve growth factor; therapy for central nervous system disorders |
| 06/10/2004 | US20040109859 Method for the treatment of multiple sclerosis |
| 06/10/2004 | US20040109858 Conformation-specific anti-von Willebrand factor antibodies |
| 06/10/2004 | US20040109854 Novel traf6 inhibiting protein |
| 06/10/2004 | US20040109853 Biological active coating components, coatings, and coated surfaces |
| 06/10/2004 | US20040109850 Treatment of bone disorders by modulation of fgfr3 |
| 06/10/2004 | US20040109848 Modulation of AP-2 alpha expression |
| 06/10/2004 | US20040109847 Treatment and prophylaxis with 4-1BB-binding agents |
| 06/10/2004 | US20040109845 Blocking activation of transglutaminase |
| 06/10/2004 | US20040109844 Methods of treating age-related defects and diseases |
| 06/10/2004 | US20040109843 Pharmaceutical composition containing decoy and use of the same |
| 06/10/2004 | US20040109827 Powdery preparations and proecss for producing the same |
| 06/10/2004 | US20040108609 Acid end group poly(D,L-lactide-co-glycolide) copolymers with high glycolide content |
| 06/10/2004 | CA2854831A1 Treatment of mammalian reaction to ige interactions |
| 06/10/2004 | CA2796924A1 Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| 06/10/2004 | CA2507616A1 Highly stable pacap/vip-derived peptides |
| 06/10/2004 | CA2507460A1 Nucleic acid comprising a sequence encoding a modified glutenin polypeptide |
| 06/10/2004 | CA2507215A1 Methods for treating cancer using porimin as a target |
| 06/10/2004 | CA2507125A1 Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| 06/10/2004 | CA2507115A1 Treatment of mammalian reaction to ige interactions |
| 06/10/2004 | CA2507045A1 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof |
| 06/10/2004 | CA2506893A1 Methods of protecting against radiation damage using alpha thymosin |
| 06/10/2004 | CA2506820A1 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene |
| 06/10/2004 | CA2506763A1 Method for expressing inducible rnai in cells, nucleic acid molecules therefor and cells transformed by said molecules |
| 06/10/2004 | CA2506738A1 Composition for treating chlamydia infections and method for identifying same |
| 06/10/2004 | CA2506683A1 Compositions and methods for cell dedifferentiation and tissue regeneration |
| 06/10/2004 | CA2506607A1 Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| 06/10/2004 | CA2506526A1 Broad spectrum anti-viral therapeutics and prophylaxis |
| 06/10/2004 | CA2506490A1 Peptide gap junction modulators |
| 06/10/2004 | CA2506411A1 Inhibitors of gst a3-3 and gst a1-1 for the treatment of cancer |
| 06/10/2004 | CA2506037A1 Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| 06/10/2004 | CA2505524A1 Novel use of erythropoietin in heart diseases |
| 06/10/2004 | CA2504561A1 Composition and method for treating lupus nephritis |
| 06/10/2004 | CA2504144A1 Compositions and methods for the diagnosis of immune related diseases using pro7 |
| 06/10/2004 | CA2503246A1 Compositions and methods for diagnosing and treating mood disorders |
| 06/10/2004 | CA2485950A1 Methods for cohort selection and longevity studies |
| 06/10/2004 | CA2476691A1 Novel proteins and nucleic acids encoding same |
| 06/09/2004 | EP1426443A1 Novel human bmcc1 gene |
| 06/09/2004 | EP1426440A1 Novel rfrp-3 and dna thereof |
| 06/09/2004 | EP1426382A1 Antiviral human serum albumin |
| 06/09/2004 | EP1426058A2 Liquid interferon-beta formulations |
| 06/09/2004 | EP1426056A1 Preventives & remedies for bone & joint diseases |
| 06/09/2004 | EP1426055A1 Targeted protein degradation vehicles (tpdvs), nucleic acid constructs encoding them and their use |
| 06/09/2004 | EP1426054A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 06/09/2004 | EP1426052A1 Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| 06/09/2004 | EP1426048A2 Treating hypertriglyceridemia with RXR agonists in combination with a PPARgamma agonist |
| 06/09/2004 | EP1426021A1 Implantable system with drug eluting cells for on-demand local drug delivery |
| 06/09/2004 | EP1425582A1 Diagnostic markers for ischemia |
| 06/09/2004 | EP1425580A2 Lymphatic endothelial cells materials and methods |
| 06/09/2004 | EP1425421A2 Polymorphisms of pd-1 |
| 06/09/2004 | EP1425409A2 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 06/09/2004 | EP1425399A2 Combinatorial methods for inducing cancer cell death |
| 06/09/2004 | EP1425396A2 Dna encoding the major allergen of plantago lanceolata pollen, pla 11 |
| 06/09/2004 | EP1425391A1 Therapeutic vaccination method, mutated peptides of hiv reverse transcriptase and their use for vaccination and diagnostic purposes |
| 06/09/2004 | EP1425390A2 Materials and methods to promote repair of nerve tissue |
| 06/09/2004 | EP1425306A2 Nanoparticles comprising biologically active tnf which is immobilised on the same |
| 06/09/2004 | EP1425305A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
| 06/09/2004 | EP1425304A2 G-csf conjugates |
| 06/09/2004 | EP1425303A2 Use of proteins for the production of a medicament for stimulating the innate non specific immune system |
| 06/09/2004 | EP1425295A1 Modified peptides and their use for the treatment of autoimmune diseases |
| 06/09/2004 | EP1425047A1 Method for improving oxygen transport by stored red blood cells |
| 06/09/2004 | EP1425046A2 Wild-type ras as a cancer therapeutic agent |
| 06/09/2004 | EP1425036A2 Virus coat protein/receptor chimeras and methods of use |
| 06/09/2004 | EP1425035A1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 06/09/2004 | EP1425034A1 Method for treating coumarin-induced hemorrhage |
| 06/09/2004 | EP1425033A2 Use of hcg and lh in controlled ovarian hyperstimulation |
| 06/09/2004 | EP1425032A2 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION |
| 06/09/2004 | EP1425031A2 Hdl for the treatment of stroke and other ischemic conditions |
| 06/09/2004 | EP1425029A1 Peptidomimetics of biologically active metallopeptides |
| 06/09/2004 | EP1425028A2 Use of il-18 inhibitors for the treatement or prevention of sepsis |
| 06/09/2004 | EP1425009A2 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 06/09/2004 | EP1425000A1 Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity |
| 06/09/2004 | EP1424999A1 Use of c2-substituted indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity |
| 06/09/2004 | EP1424998A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 06/09/2004 | EP1424994A1 Preparation of sustained release pharmaceutical composition |
| 06/09/2004 | EP1424985A1 Use of derivatives of c2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity |
| 06/09/2004 | EP1424957A2 Microfabricated nanopore device for sustained release of therapeutic agent |
| 06/09/2004 | EP1424898A1 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 06/09/2004 | EP1424897A2 Compositions and methods for treatment of cancer |
| 06/09/2004 | EP1424896A1 Method for expression of small rna molecules within a cell |